Genetic determinants of vascular reactivity

Current Hypertension Reports

Volumn 4, Issue 1, 2002, Pages 41-48

  Henrion, Daniel ^a   Benessiano, Joelle ^a   Iglarz, Marc ^a   Philip, Ivan ^a   Levy, Bernard I ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN; ENDOTHELIN 1; NITRIC OXIDE SYNTHASE; PROTEIN PRECURSOR;

BLOOD PRESSURE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; HYPERTENSION; METABOLISM; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; BLOOD PRESSURE; BLOOD VESSELS; CARDIOVASCULAR DISEASES; ENDOTHELIN-1; ENDOTHELINS; GENOTYPE; HUMANS; HYPERTENSION; NITRIC OXIDE SYNTHASE; POLYMORPHISM, GENETIC; PROTEIN PRECURSORS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0036484092     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-002-0052-z     Document Type: Article

References (56)

1. Colhoun H: Confirmation needed for genes for hypertension. Commentaty. Lancet 1999, 353:1200-1201.
2. Ely D, Turner M, Milsted A: Review of the Y chromosome and hypertension. Braz J Med Biol Res 2000, 33:679-691.
3. Vicaut E: Microcirculation and arterial hypertension. Drugs 1999, 59:1-10.
4. Davis MJ, Hill MA: Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999, 79:387-423.
5. Henrion D, Benessiano J, Philip I., et al.: The deletion genotype of the angiotensin I-converting enzyme is associated with an increased vascular reactivity in vivo and in vitro. J Am Coll Cardiol 1999, 34:830-836.
6. Lyons D, Webster J, Benjamin N: Angiotensin II. Adrenergic sympathetic constrictor action in humans. Circulation 1995, 91: 1457-1460.
7. Seidelin PH, Collier JG, Struthers A.D., et al.: Angiotensin II augments sympathetically mediated arteriolar constriction in man. Clin Sci (Colch) 1991, 81: 261-266.
8. Henrion D, Amant C, Benessiano J., et al.: Angiotensin II type 1 receptor gene polymorphism is associated with an increased vascular reactivity in the human mammary artery in vitro. J Vasc Res 1998, 35:356-362.
9. Henrion D, Laher I, Laporte R., et al.: Angiotensin II amplifies arterial contractile response to norepinephrine without increasing Ca++ influx: role of protein kinase C. J Pharmacol Exp Ther 1992, 261:835-840.
10. Rigat B, Hubert C, Alhenc-Gelas F, et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
11. Bonnardeaux A, Davies E, Jeunemaitre X., et al.: Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994, 24:63-69.
12. Jeunemaitre X, Soubrier F, Kotelevtsev Y.V., et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71: 169-180.
13. Wang JG, Staessen JA: Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000, 410: 289-302.
14. Danser AH, Schalekamp MA, Bax W.A., et al.: Angiotensin-con-verting enzyme in the human heart. Effect of the deletion/ insertion polymorphism. Circulation 1995, 92:1387-1388.
15. Ueda S, Elliott HL, Morton J.J., et al.: Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension 1995, 25:1266-1269.
16. Buikema H, Pinto YM, Rooks G, et al: The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996, 17:787-794.
17. Chadwick IG, O'Toole L, Morice AH, et al: Pressor and hormonal responses to angiotensin I infusion in healthy subjects of different angiotensin- converting enzyme genotypes. J Cardiovasc Pharmacol 1997, 29:485-489.
18. Gainer JV, Stein CM, Neal T, et al: Interactive effect of ethnicity and ACE insertion/deletion polymorphism on vascular reactivity. Hypertension 2001, 37:46-51.
19. Castellano M, Muiesan ML, Rizzoni D, et al: Angiotensin-con-verting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study. Circulation 1995, 91: 2721-2724.
20. Girerd X, Hanon O, Mourad J.J., et al.: Lack of association between renin-angiotensin system, gene polymorphisms, and wall thickness of the radial and carotid arteries. Hypertension 1998, 32:579-583.
21. Steeds RP, Toole LO, Channer K.S., et al.: Human vascular reactivity and polymorphisms of the angiotensin-converting enzyme and the angiotensin type 1 receptor genes. J Vasc Res 1999, 36:445-455.
22. Perticone F, Ceravolo R, Maio R., et al.: Angiotensin-converting enzyme gene polymorphism is associated with endothelium-dependent vasodilation in never treated hypertensive patients. Hypertension 1998, 31900-905.
23. Butler R, Morris AD, Burchell B, et al: DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension 1999, 33:1164-1168.
24. Kario K, Matsuo T, Kobayashi H., et al.: Endothelial cell damage and angiotensin-converting enzyme insertion/deletion genotype in elderly hypertensive patients. J Am Coll Cardiol 1998, 32:444-450.
25. Prasad A, Narayanan S, Waclawiw M.A., et al.: The insertion/ deletion polymorphism of the angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity. J Am Coll Cardiol 2000, 36:1579-1586.
26. Kanazawa H, Okamoto T, Hirata K., et al.: Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:1235-1238.
27. Butler R: The DD-ACE genotype and cardiovascular disease. Pharmacogenomics 2000, 1:153-167.
28. Danser AH, Schunkert H: Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol 2000, 410:303-316.
29. Amouyel P, Richard F, Berr C., et al.: The renin angiotensin system and Alzheimer's disease. Ann N Y Acad Sci 2000, 903:437-441.
30. van Geel P.P., Pinto YM, Voors A.A., et al.: Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000, 35:717-721.
31. Spiering W, Kroon AA, Fuss-Lejeune MM, et al.: Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 2000, 36:411-416.
32. Benetos A, Gautier S, Ricard S., et al.: Influence of angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996, 94:698-703.
33. Amant C, Hamon M, Bauters C., et al.: The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction. J Am Coll Cardiol 1997, 29:486-490.
34. Pethig K, Heublein B, Hoffmann A., et al.: ACE-gene polymorphism is associated with the development of allograft vascular disease in heart transplant recipients. J Heart Lung Transplant 2000, 19:1175-1182.
35. Tiret L, Bonnardeaux A, Poirier O., et al.: Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994, 344:910-913.
36. Azizi M, Hallouin MC, Jeunemaitre X, et al: Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration. J Clin Endocrinol Metab 2000, 85:4331-4337.
37. Winkelmann BR, Russ AP, Nauck M, et al: Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999, 137:698-705.
38. Haynes WG, Ferro CJ, O'Kane KP, et al: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996, 93:1860-1870.
39. Tiret L, Poirier O, Hallet V., et al.: The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999, 33:1169-1174.
40. Iglarz M, Benessiano J, Philip I., et al.: The Pre-pro-endothelin gene polymorphism is associated with an change in vascular reactivity in human internal mammary arteries. Hypertension 1999, 34:696.
41. Miyamoto Y, Saito Y, Kajiyama N., et al.: Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998, 32:3-8.
42. Paillard F, Chansel D, Brand E., et al.: Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 1999, 34:423-429.
43. Schneider MP, Erdmann J, Delles C., et al.: Functional gene testing of the Glu298Asp polymorphism of the endothelial NO synthase. J Hypertens 2000, 18:1767-1773.
44. Philip I, Plantefeve G, Vuillaumier-Barrot S, et al.: G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine. Circulation 1999, 99:3096-3098.
45. Tsukada T, Yokoyama K, Arai T., et al.: Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998, 245:190-193.
46. Houle S, Landry M, Audet R., et al.: Effect of allelic polymorphism of the B(1) and B(2) receptor genes on the contractile responses of the human umbilical vein to kinins. J Pharmacol Exp Ther 2000, 294:45-51.
47. Iwai N, Katsuya T, Ishikawa K., et al.: Human prostacyclin syn-thase gene and hypertension: the Suita Study. Circulation 1999, 100:2231-2236.
48. Griendling KK, Sorescu D, Lassegue B., et al.: Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and patho-physiology. Arterioscler Thromb Vasc Biol 2000, 20:2175-2183.
49. Ito D, Murata M, Watanabe K., et al.: C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovas-cular disease in the Japanese population. Stroke 2000, 31: 936-939.
50. Guzik TJ, West NE, Black E, et al: Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000, 102: 1744-1747.
51. Bauters C, Amant C, Boullier A., et al.: Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation 2000, 101: 740-743.
52. Snapir A, Heinonen P, Tuomainen T.P., et al.: An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol 2001, 37:1516-1522.
53. Hoit BD, Suresh DP, Craft L, et al: Beta2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000, 139:537-542.
54. Xie HG, Stein CM, Kim R.B., et al.: Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 1999, 9:511-516.
55. Renner W, Schallmoser K, Gallippi P., et al.: C242T polymorphism of the p22 phox gene is not associated with peripheral arterial occlusive disease. Atherosclerosis 2000, 152:175-179.
56. James RW, Leviev I, Ruiz J., et al.: Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000, 49:1390-1393.